Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of Brentuximab Vedotin Plus Lenalidomide in Patients With Relapsed/ Refractory Cutaneous T-Cell Lymphomas

NCT03373305 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03373305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03373305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of Brentuximab Vedotin Plus Lenalidomide in Patients With Relapsed/ Refractory Cutaneous T-Cell Lymphomas
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Withdrawn
Start date
March 31, 2019
Completion date
April 26, 2019
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd30-positive neoplastic cells present, folliculotropic mycosis fungoides, recurrent mycosis fungoides, recurrent primary cutaneous t-cell non-hodgkin lymphoma, refractory mycosis fungoides, refractory primary cutaneous t-cell non-hodgkin lymphoma, sezary syndrome